As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...

Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like SAR444656 and amlitelimab in development.

The following is a summary of “Exploring itch in hidradenitis suppurativa with lessons from atopic dermatitis and psoriasis,” ...